Back

Is there a difference in treatment persistence across oral anticoagulants? Results of a UK cohort study evaluating oral anticoagulation therapy in an atrial fibrillation population

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Ms Gillian Stynes

Uxbridge (United Kingdom of Great Britain & Northern Ireland)

20 More presentations in this session

Presentation thumbnail
Prothrombin activation fragment (F1+2) as an index of anticoagulant therapy with factor Xa inhibitor in atrial fibrillation
Doctor E. Ueno (Kahoku, JP)
Abstract
Presentation thumbnail
Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study
Professor G. Lip (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Differences in the characteristics of patients with non-valvular atrial fibrillation who are newly prescribed apixaban, rivaroxaban, dabigatran and VKA in general practice in the UK
Ms G. Stynes (Uxbridge, GB)
Abstract Slides
Presentation thumbnail
The HAS-BLED score for prediction of stroke and systemic embolism: insights from the PREvention oF thromboembolic events, European Registry in Atrial Fibrillation (PREFER in AF)
Doctor M. Rohla (Bern, CH)
Abstract
Presentation thumbnail
Anticoagulation management in patients with atrial fibrillation undergoing elective electrical cardioversion
Doctor O. Erkuner (Heerlen, NL)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources